Translating patient-derived xenograft tumor growth inhibition data to clinical dose–response prediction for antibody-drug conjugates: a QSP modeling approach
Year: 2026
Type: article
Abstract: Introduction Antibody-drug conjugates (ADCs) represent a transformative oncology modality, yet existing model-informed drug development (MIDD) methods have not yet demonstrated satisfactory predictive performance for clinical efficacy. Methods Here we develop a model-based framework that integrated patient-derived xenograft (PDX) data with quantitative systems pharmacology (QSP) modeling and virtual patient population simulations to predict clinical patient response in terms of objective response rates (ORR). The QSP model mechanistically incorporated compartmental ADC metabolism and pharmacokinetic distribution, receptor-mediated ADC tumor cell disposition, payload bystander effect and tumor killing. Data of two HER2-ADCs, trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) were used as case demonstrations. Results The QSP model framework was successfully parameterized to capture tumor growth inhibition dynamics across 16 different HER2-expressing PDX models, and by formulating model-based virtual patients, it is shown that simulation-predicted clinical ORR for T-DXd can match with the ranges observed across actual T-DXd trials. Simulated dose–ORR relationship identified a dosage of about 5-6 mg/kg Q3W for T-DXd as the optimal clinical dose, beyond which further dose escalation yields diminishing returns, and the clinical utility and generalizability of this framework is again verified using PDX-clinical data of T-DM1. Sequencing and bioinformatics analysis further suggested that immune plus fibrotic status in tumor microenvironment may together contribute to ADC efficacy stratification. Discussion In summary, this PDX-informed QSP modeling framework can serve as a translational tool to prospectively evaluate clinically dose-response relationships and design clinical dose escalation strategy for ADC drug development.
Source: Frontiers in Immunology
Authors: Yumeng Zheng(Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Yiwen Ma(Data curation, Investigation, Visualization, Writing – review & editing), Wenyuan Nie(Data curation, Visualization, Writing – review & editing), Diandong Jiang(Data curation, Methodology, Resources, Writing – review & editing), Xiaorong Gu(Data curation, Methodology, Resources, Writing – review & editing), Hongkui Chen(Data curation, Methodology, Resources, Writing – review & editing), Yuan Gao(Methodology, Resources, Writing – review & editing), Qi Fu(Data curation, Methodology, Writing – review & editing), Danyi Wen(Conceptualization, Methodology, Resources, Writing – original draft, Writing – review & editing), Chen Zhao(Conceptualization, Methodology, Resources, Writing – original draft, Writing – review & editing)
Institutions: Nanjing Medical University, Jiangsu Province Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: antibody-drug conjugates, patient-derived xenografts, quantitative systems pharmacology, dose-response prediction, trastuzumab deruxtecan, trastuzumab emtansine, HER2-positive breast cancer, objective response rate, virtual patient simulation, tumor growth inhibition, bystander effect, tumor microenvironment, immune status, fibrosis, model-informed drug development, dose escalation
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234717061
